Cervical cancer is the cancer with the fourth highest mortality rate among women worldwide. Locally advanced cervical cancer (LACC) is treated with a combination of external and internal radiotherapy (brachytherapy) and chemotherapy. For the first time, a study conducted by a research group at the Comprehensive Cancer Center Vienna of MedUni Vienna and Vienna General Hospital using data from the multicentre EMBRACE-I trial demonstrated the superiority of a targeted approach in brachytherapy. The results have just been published online in the Journal of Clinical Oncology and are the basis for customized treatment for patients.
Locally advanced cervical cancer: Better odds using personalized brachytherapy
Cervical cancer is the cancer with the fourth highest mortality rate among women worldwide. Locally advanced cervical cancer (LACC) is treated with a combination of external and internal radiotherapy (brachytherapy) and chemotherapy. For the first time, a study conducted by a research group at the Comprehensive Cancer Center Vienna of MedUni Vienna and Vienna General Hospital using data from the multicentre EMBRACE-I trial demonstrated the superiority of a targeted approach in brachytherapy. The results have just been published online in the Journal of Clinical Oncology and are the basis for customized treatment for patients.